Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Novacyt ( (FR:ALNOV) ).
Novacyt S.A. has provided an update on its liquidity agreement with Invest Securities SA, detailing the purchase and sale of its ordinary shares for the month of June 2025. The company reported that 26,017 shares were purchased and 12,921 shares were sold under the agreement, with a total of 104,002 shares held in treasury as of June 30, 2025. The total number of ordinary shares stands at 70,626,248, which is relevant for shareholders to determine their notification obligations under French law. This update reflects Novacyt’s ongoing efforts to manage its share liquidity and maintain transparency with its stakeholders.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, focusing on genomic medicine. It develops, manufactures, and commercializes molecular assays and instrumentation to provide seamless solutions from sample to result across sectors such as human health, animal health, and environmental. The company operates in three segments: Clinical, Instrumentation, and Research Use Only, and has a presence in over 65 countries.
See more data about ALNOV stock on TipRanks’ Stock Analysis page.